Page last updated: 2024-08-25

rosiglitazone and Hyperlipemia

rosiglitazone has been researched along with Hyperlipemia in 34 studies

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (2.94)18.2507
2000's22 (64.71)29.6817
2010's11 (32.35)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM1
Bajji, AC; Chakrabarti, R; Juluri, S; Kalchar, S; Lohray, BB; Lohray, VB; Mamidi, NV; Misra, P; Padakanti, S; Poondra, RR; Rajagopalan, R; Vikramadithyan, RK1
Biller, SA; Cap, M; Chandrasena, G; Chang, SY; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, A; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Harrity, T; Humphreys, WG; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ren, J; Ryono, DE; Sasseville, VG; Seethala, R; Selan, F; Shao, C; Sleph, P; Sun, W; Tieman, A; Wang, W; Wetterau, JR; Zhang, H1
Berger, JP; Doebber, TW; Forrest, MJ; Jones, AB; Liu, K; Macnaul, KL; Moller, DE; Xu, L; Zhou, G1
Bullock, WH; Burns, M; Chen, L; Claus, T; Daly, M; Dela Cruz, FE; Ehrgott, FJ; Johnson, JS; Livingston, JN; Ma, X; Majumdar, D; Rudolph, J; Schoenleber, RW; Shapiro, J; Tsutsumi, M; Yang, L1
Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS1
Aragonès, G; Beltrán-Debón, R; Camps, J; García-Heredia, A; Geeraert, B; Holvoet, P; Joven, J; Pedro-Botet, J; Rodríguez-Gallego, E; Rull, A1
Kuo, YH; Lin, CH; Shih, CC1
Ji, K; Wang, H; Wang, R; Wu, X; Yan, Z; Zang, B1
Ho, HY; Jian, JY; Lin, CH; Shih, CC; Wu, JB1
Du, X; Gao, M; Li, L; Liao, J; Liu, G; Qi, Y; Wang, M; Wang, Y; Yang, H1
Gaikwad, AB; Pathan, AR; Ramarao, P; Viswanad, B1
Distrutti, E; Fiorucci, S; Mencarelli, A; Renga, B1
Srivastava, RA2
Zhou, JY; Zhou, SW1
Cabezas, MC; Dallinga-Thie, G; de Koning, EJ; Hoepelman, AI; Rabelink, TJ; van Wijk, JP1
Chang, B; Chen, L; Dong, L; Li, M; Li, XY; Lian, FM; Liu, WK; Qin, PJ; Tong, XL; Wang, J; Yu, B; Zhang, JH; Zhen, Z1
Feng, Y; Ruan, KF; Wang, LY; Wang, S; Wang, Y; Xu, DS1
Viberti, GC1
Acerini, CL; Agostini, M; Bell, JD; Boiani, R; Chatterjee, VK; Cinti, S; Dixon, AK; Dunne, F; Gurnell, M; Jebb, SA; Karpe, F; O'Rahilly, S; Savage, DB; Tan, GD; Thomas, EL; Umpleby, AM; Vidal-Puig, A; Williams, RL1
Chilton, RJ; Stolar, MW1
Henry, RR1
Kiselevich, A; London, D; Magen, E; Priluk, R; Viskoper, RJ; Volchek, L; Yosefy, C1
Collins, JN; Gee, MK; Kauffman, RF; Rankin, SE; Wagner, JD; Zhang, L1
Gavrilova, O; Haluzik, M; Kim, H; LeRoith, D; Pajvani, UB; Portas, J; Scherer, PE; Sun, H; Yakar, S1
Barr, R; Bensch, WR; Brozinick, JT; Bull, C; Dana, S; Hawkins, E; Klausing, K; Martin, JA; Otto, K; Rafaeloff-Phail, R; Rafizadeh-Montrose, C; Reifel-Miller, A; Rhodes, G; Robey, R; Rojo, I; Rungta, D; Snyder, D; Warshawsky, A; Wilbur, K; Zhang, T; Zink, R1
Mukhtar, R; Reckless, JP1
Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Pinaire, JA; Tan, MH; Zagar, AJ1
Biller, S; Cap, M; Chen, S; Cheng, PT; Chu, C; Devasthale, P; Farrelly, D; Fenderson, W; Gregg, R; Gu, L; Hariharan, N; Harrity, T; Jeon, Y; Kunselman, L; Mookhtiar, KA; Ponticiello, R; Qu, F; Ren, J; Ryono, D; Seethala, R; Shao, C; Tieman, A; Wang, W; Wetterau, J; Yang, WP; Zhang, H; Zhou, M1
Albert, AJ; Cong, Z; Gabbay, RA; Gilliland, KL; Liu, W; Mauger, DT; Nelson, AM; Rosamilia, LL; Sivarajah, S; Thiboutot, DM; Trivedi, NR1
Vergès, B1
Abram, SR; Carter, C; Dearman, J; Hester, RL; Xiang, L1
Chinetti, G; Delerive, P; Fadel, A; Fruchart, JC; Habib, A; Koenig, W; Lebret, M; Maclouf, J; Merval, R; Najib, J; Staels, B; Tedgui, A; Torra, IP1

Reviews

6 review(s) available for rosiglitazone and Hyperlipemia

ArticleYear
The PPARs: from orphan receptors to drug discovery.
    Journal of medicinal chemistry, 2000, Feb-24, Volume: 43, Issue:4

    Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors

2000
Rosiglitazone: potential beneficial impact on cardiovascular disease.
    International journal of clinical practice, 2003, Volume: 57, Issue:2

    Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones

2003
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
    Clinical therapeutics, 2003, Volume: 25 Suppl B

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemodynamics; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones

2003
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
    Clinical therapeutics, 2003, Volume: 25 Suppl B

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors

2003
Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22 Suppl 3

    Topics: Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hyperlipidemias; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazolidinediones

2005
Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.
    Fundamental & clinical pharmacology, 2007, Volume: 21 Suppl 2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazolidinediones

2007

Trials

4 trial(s) available for rosiglitazone and Hyperlipemia

ArticleYear
Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy.
    Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:1

    Topics: Area Under Curve; Biomarkers; Cholesterol; Fatty Acids, Nonesterified; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxybutyrates; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Netherlands; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides

2011
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
    Journal of cardiovascular pharmacology, 2004, Volume: 44, Issue:2

    Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, LDL; Cilazapril; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Evoked Potentials; Female; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Kidney; Male; Rosiglitazone; Simvastatin; Skin Physiological Phenomena; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Ultrasonography; Vasodilation

2004
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Diabetes care, 2005, Volume: 28, Issue:7

    Topics: Aged; Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Thiazolidinediones; Triglycerides

2005
Peroxisome proliferator-activated receptors increase human sebum production.
    The Journal of investigative dermatology, 2006, Volume: 126, Issue:9

    Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isotretinoin; Ligands; Lipogenesis; Male; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Sebaceous Glands; Sebum; Thiazolidinediones

2006

Other Studies

24 other study(ies) available for rosiglitazone and Hyperlipemia

ArticleYear
(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.
    Journal of medicinal chemistry, 2001, Aug-02, Volume: 44, Issue:16

    Topics: Animals; Biological Availability; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Mice; Oxazines; Phenylpropionates; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors; Triglycerides

2001
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Obese; Oxazoles; PPAR alpha; PPAR gamma; Transcriptional Activation; Triglycerides

2005
Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
    Journal of medicinal chemistry, 2005, Apr-07, Volume: 48, Issue:7

    Topics: 3T3-L1 Cells; Animals; Blood Glucose; Carrier Proteins; Chlorocebus aethiops; Cholesterol; COS Cells; Diabetes Mellitus, Type 2; Dogs; Fatty Acid-Binding Proteins; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isoxazoles; Mice; Mice, Obese; PPAR alpha; PPAR gamma; Propionates; Radioligand Assay; RNA, Messenger; Structure-Activity Relationship; Transcriptional Activation; Triglycerides; Weight Gain

2005
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
    Journal of medicinal chemistry, 2007, Mar-08, Volume: 50, Issue:5

    Topics: Acetates; Animals; Apolipoprotein A-I; Cell Line; Cricetinae; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; In Vitro Techniques; Indans; Lipids; Male; Mice; Mice, Transgenic; PPAR alpha; PPAR delta; PPAR gamma; Radioligand Assay; Rats; Rats, Zucker; Solubility; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation; Triazoles

2007
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:8

    Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult

2017
Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study.
    Journal of proteome research, 2014, Mar-07, Volume: 13, Issue:3

    Topics: Animals; Disease Models, Animal; Fatty Liver; Fenofibrate; Gene Expression Profiling; Gene Expression Regulation; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Metabolome; Mice; Mice, Transgenic; Obesity; Peroxisome Proliferator-Activated Receptors; Protein Interaction Mapping; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcriptome

2014
Effects of Bofu-Tsusho-San on diabetes and hyperlipidemia associated with AMP-activated protein kinase and glucose transporter 4 in high-fat-fed mice.
    International journal of molecular sciences, 2014, Nov-04, Volume: 15, Issue:11

    Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet, High-Fat; Down-Regulation; Drugs, Chinese Herbal; Fatty Acid Synthases; Gluconeogenesis; Glucose Transporter Type 4; Hyperlipidemias; Liver; Male; Mice; Mice, Inbred C57BL; Phosphorylation; PPAR alpha; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones

2014
Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:5

    Topics: Acute Kidney Injury; Animals; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Hyperlipidemias; Hypoglycemic Agents; Immunohistochemistry; In Situ Nick-End Labeling; Male; Pancreatitis; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones

2015
(-)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana, Prevents Diabetes and Hyperlipidemia by Regulation of Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice.
    International journal of molecular sciences, 2015, Oct-20, Volume: 16, Issue:10

    Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fenofibrate; Hyperlipidemias; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Plants, Medicinal; Rosiglitazone; Thiazolidinediones

2015
Adipose tissue deficiency results in severe hyperlipidemia and atherosclerosis in the low-density lipoprotein receptor knockout mice.
    Biochimica et biophysica acta, 2016, Volume: 1861, Issue:5

    Topics: Adipose Tissue; Adiposity; Animals; Atherosclerosis; Cholesterol; Diet, High-Fat; Disease Models, Animal; Genetic Predisposition to Disease; GTP-Binding Protein gamma Subunits; Heterotrimeric GTP-Binding Proteins; Hyperlipidemias; Hypolipidemic Agents; Macrophages; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Receptors, LDL; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Time Factors

2016
Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats.
    European journal of pharmacology, 2008, Jul-28, Volume: 589, Issue:1-3

    Topics: Animals; Behavior, Animal; Blood Glucose; Cognition; Dietary Fats; Disease Models, Animal; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Maze Learning; Memory; Motor Activity; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Time Factors

2008
Antiatherosclerotic effect of farnesoid X receptor.
    American journal of physiology. Heart and circulatory physiology, 2009, Volume: 296, Issue:2

    Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cardiovascular Agents; CD11b Antigen; CD36 Antigens; Chenodeoxycholic Acid; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Hyperlipidemias; Interleukin-1beta; Interleukin-6; Ligands; Lipids; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Toll-Like Receptor 4; Transcription Factors; Tumor Necrosis Factor-alpha

2009
Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
    European journal of pharmacology, 2009, Apr-01, Volume: 607, Issue:1-3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diacylglycerol O-Acyltransferase; DNA-Binding Proteins; Down-Regulation; Drug Interactions; Fenofibrate; Hydrocarbons, Fluorinated; Hyperlipidemias; Hypolipidemic Agents; Liver X Receptors; Male; Mice; Orphan Nuclear Receptors; Phosphoenolpyruvate Carboxykinase (GTP); PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfonamides; Thiazolidinediones; Triglycerides

2009
Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver.
    Fitoterapia, 2011, Volume: 82, Issue:2

    Topics: Animals; Antioxidants; Berberine; Coptis; Cyclin T; Cyclin-Dependent Kinase 9; Diabetes Mellitus, Experimental; Diet; Drugs, Chinese Herbal; Enzymes; Fenofibrate; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Peroxidation; Liver; Male; Malondialdehyde; Phytotherapy; Positive Transcriptional Elongation Factor B; Rats; Rats, Wistar; Rhizome; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Up-Regulation

2011
Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
    Atherosclerosis, 2011, Volume: 214, Issue:1

    Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cricetinae; Fatty Acids; Female; Fenofibrate; Hydrocarbons, Fluorinated; Hyperlipidemias; Liver X Receptors; Male; Mesocricetus; Orphan Nuclear Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Sulfonamides; Thiazolidinediones; Triglycerides

2011
Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats.
    The American journal of Chinese medicine, 2011, Volume: 39, Issue:1

    Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Area Under Curve; Blood Glucose; Bupleurum; Coptis; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glucose Tolerance Test; Glucose Transporter Type 4; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipid Metabolism; Lipids; Muscle, Skeletal; Phytotherapy; Rats; Rats, Inbred OLETF; Rheum; Rosiglitazone; Scutellaria baicalensis; Thiazolidinediones

2011
MDG-1, a polysaccharide from Ophiopogon japonicus exerts hypoglycemic effects through the PI3K/Akt pathway in a diabetic KKAy mouse model.
    Journal of ethnopharmacology, 2012, Aug-30, Volume: 143, Issue:1

    Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experimental; Female; Glucose Tolerance Test; Glucose Transporter Type 4; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Mice, Inbred C57BL; Ophiopogon; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Plant Roots; Polysaccharides; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides

2012
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
    Diabetes, 2003, Volume: 52, Issue:4

    Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Female; Gene Expression; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Liver; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Mutation; Neoplasm Proteins; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Suppressor Proteins

2003
Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
    Metabolism: clinical and experimental, 2004, Volume: 53, Issue:9

    Topics: Animals; Biomarkers; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hyperlipidemias; Hypoglycemic Agents; Insulin; Lipids; Macaca fascicularis; Male; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Characteristics; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Necrosis Factor-alpha

2004
Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
    Diabetologia, 2004, Volume: 47, Issue:12

    Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Transgenic; PPAR gamma; Rosiglitazone; Thiazolidinediones

2004
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Molecular endocrinology (Baltimore, Md.), 2005, Volume: 19, Issue:6

    Topics: Adiponectin; Alkynes; Animals; Binding, Competitive; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Cinnamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fenofibrate; Gene Expression Regulation, Enzymologic; Glucose; Homozygote; Humans; Hyperlipidemias; In Vitro Techniques; Insulin; Intercellular Signaling Peptides and Proteins; Kinetics; Lipid Metabolism; Liver; Male; Mice; Mice, Transgenic; Models, Chemical; PPAR alpha; PPAR gamma; Protein Binding; Protein Isoforms; Rats; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Triglycerides; Two-Hybrid System Techniques

2005
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Diabetes, 2006, Volume: 55, Issue:1

    Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycine; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Mice; Obesity; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones

2006
Insulin resistance and impaired functional vasodilation in obese Zucker rats.
    American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:4

    Topics: Animals; Antioxidants; Arachidonic Acid; Arterioles; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Disease Models, Animal; Electric Stimulation; Fatty Acids, Unsaturated; Hydrazines; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Kidney Cortex; Male; Muscle, Skeletal; NADPH Oxidases; Obesity; Oxidative Stress; Rats; Rats, Zucker; Receptors, Thromboxane; Rosiglitazone; Spin Labels; Superoxides; Thiazolidinediones; Thromboxanes; Time Factors; Triglycerides; Vasoconstriction; Vasodilation

2008
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
    Nature, 1998, Jun-25, Volume: 393, Issue:6687

    Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Enzymologic; Humans; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Interleukin-1; Interleukin-6; Isoenzymes; Membrane Proteins; Muscle, Smooth, Vascular; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic

1998